↓ Skip to main content

Cochrane Database of Systematic Reviews

Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease

Overview of attention for article published in Cochrane database of systematic reviews, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news
1 news outlet
twitter
32 X users
facebook
4 Facebook pages
wikipedia
6 Wikipedia pages

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
224 Mendeley
Title
Indacaterol, a once‐daily beta<sub>2</sub>‐agonist, versus twice‐daily beta<sub>2</sub>‐agonists or placebo for chronic obstructive pulmonary disease
Published in
Cochrane database of systematic reviews, January 2015
DOI 10.1002/14651858.cd010139.pub2
Pubmed ID
Authors

James B Geake, Eli J Dabscheck, Richard Wood‐Baker, Christopher J Cates

X Demographics

X Demographics

The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 224 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 1 <1%
Sweden 1 <1%
Unknown 220 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 29 13%
Researcher 25 11%
Student > Ph. D. Student 21 9%
Student > Bachelor 21 9%
Student > Doctoral Student 13 6%
Other 38 17%
Unknown 77 34%
Readers by discipline Count As %
Medicine and Dentistry 79 35%
Nursing and Health Professions 25 11%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Social Sciences 7 3%
Psychology 6 3%
Other 18 8%
Unknown 80 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2022.
All research outputs
#1,218,477
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#2,549
of 11,842 outputs
Outputs of similar age
#15,903
of 358,658 outputs
Outputs of similar age from Cochrane database of systematic reviews
#57
of 281 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 358,658 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 281 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.